TY - JOUR
T1 - Kidney function is associated with plasma ATN biomarkers among Hispanics/Latinos
T2 - SOL-INCA and HCHS/SOL results
AU - Anita, Natasha Z.
AU - Tarraf, Wassim
AU - Kuwayama, Sayaka
AU - Márquez, Freddie
AU - DeCarli, Charles
AU - Thyagarajan, Bharat
AU - Franceschini, Nora
AU - Lash, James P.
AU - Johns, Tanya
AU - González, Kevin A.
AU - Daviglus, Martha
AU - Zhou, Haibo
AU - Stickel, Ariana M.
AU - Penedo, Frank J.
AU - Rundek, Tatjana
AU - Galasko, Doug
AU - González, Hector M.
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - Background: Plasma amyloid-tau-neurodegeneration (ATN) biomarker levels may be influenced by non-brain systems, such as kidney function, which could impact the interpretation of ATN biomarker results, particularly in groups like Hispanic/Latino individuals with higher rates of cardiometabolic health issues. Here, we examine the association between kidney function and plasma ATN markers among a diverse sample of Hispanic/Latino individuals living in the U.S. Methods: Data was collected from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL, Visit 1, 2008–2011), the largest prospective cohort study of noninstitutionalized Hispanic/Latino adults in the U.S., and its ancillary study, the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA) which was conducted during the second visit of the parent HCHS/SOL study (Visit 2, 2015–2018). SOL-INCA aimed to examine the neurocognitive decline of middle-aged and older Hispanic/Latino adults, and the inclusion criteria were the age of 50-years and older by Visit 2 and completion of battery of neurocognitive tests at Visit 1. Survey linear regression models were used to examine associations between CKD status (estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73m2 or urine albumin-creatinine ratio [uACR]) > = 30 mg/g) and the plasma ATN biomarkers (β-amyloid 42/40 ratio [Aβ42/40 ratio], phosphorylated-tau181 [p-Tau181], neurofilament light [NfL], and glial fibrillary associated protein [GFAP]), independently. All models adjusted for sociodemographic and cardiometabolic factors (BMI, diabetes, and hypertension). Results: 5,968 participants were included in the study (mean age 63.4 ± 8.1, 54% women). CKD was associated with higher p-Tau181 (b = 0.82), NfL (b = 11.60) and GFAP levels (b = 31.41), and lower Aβ42/Aβ40 ratio (b=-0.004). Lower eGFR (i.e., reduced kidney function) was associated with higher p-Tau181, NfL, and GFAP levels (b ranges [-0.87 - -0.03]), and lower Aβ42/Aβ40 ratio (b = 0.000). Higher (natural log) uACR was associated with lower Aβ42/Aβ40 ratio and higher levels of all other biomarkers (b ranges [0.24–5.49]). Additionally, CKD, eGFR, and uACR were associated with ATN biomarkers in models adjusted for cardiometabolic risk factors, diabetes and hypertension. Conclusions: CKD status, kidney function and urinary markers of kidney damage are significant confounders in the interpretation of plasma ATN biomarker levels.
AB - Background: Plasma amyloid-tau-neurodegeneration (ATN) biomarker levels may be influenced by non-brain systems, such as kidney function, which could impact the interpretation of ATN biomarker results, particularly in groups like Hispanic/Latino individuals with higher rates of cardiometabolic health issues. Here, we examine the association between kidney function and plasma ATN markers among a diverse sample of Hispanic/Latino individuals living in the U.S. Methods: Data was collected from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL, Visit 1, 2008–2011), the largest prospective cohort study of noninstitutionalized Hispanic/Latino adults in the U.S., and its ancillary study, the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA) which was conducted during the second visit of the parent HCHS/SOL study (Visit 2, 2015–2018). SOL-INCA aimed to examine the neurocognitive decline of middle-aged and older Hispanic/Latino adults, and the inclusion criteria were the age of 50-years and older by Visit 2 and completion of battery of neurocognitive tests at Visit 1. Survey linear regression models were used to examine associations between CKD status (estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73m2 or urine albumin-creatinine ratio [uACR]) > = 30 mg/g) and the plasma ATN biomarkers (β-amyloid 42/40 ratio [Aβ42/40 ratio], phosphorylated-tau181 [p-Tau181], neurofilament light [NfL], and glial fibrillary associated protein [GFAP]), independently. All models adjusted for sociodemographic and cardiometabolic factors (BMI, diabetes, and hypertension). Results: 5,968 participants were included in the study (mean age 63.4 ± 8.1, 54% women). CKD was associated with higher p-Tau181 (b = 0.82), NfL (b = 11.60) and GFAP levels (b = 31.41), and lower Aβ42/Aβ40 ratio (b=-0.004). Lower eGFR (i.e., reduced kidney function) was associated with higher p-Tau181, NfL, and GFAP levels (b ranges [-0.87 - -0.03]), and lower Aβ42/Aβ40 ratio (b = 0.000). Higher (natural log) uACR was associated with lower Aβ42/Aβ40 ratio and higher levels of all other biomarkers (b ranges [0.24–5.49]). Additionally, CKD, eGFR, and uACR were associated with ATN biomarkers in models adjusted for cardiometabolic risk factors, diabetes and hypertension. Conclusions: CKD status, kidney function and urinary markers of kidney damage are significant confounders in the interpretation of plasma ATN biomarker levels.
KW - Alzheimer's disease
KW - Biomarkers
KW - Dementia
KW - Kidney
KW - Renal
UR - https://www.scopus.com/pages/publications/105008701733
UR - https://www.scopus.com/pages/publications/105008701733#tab=citedBy
U2 - 10.1186/s13195-025-01786-8
DO - 10.1186/s13195-025-01786-8
M3 - Article
C2 - 40537838
AN - SCOPUS:105008701733
SN - 1758-9193
VL - 17
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
IS - 1
M1 - 137
ER -